The full report of the results of the LILAC-2 study has been published this week -
Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results from the open-label LILAC-2 study
This was one of the presentations made by Acadia at the recent IRSF Scientific Meeting.
Acadia, page-627
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.65 |
Change
0.000(0.00%) |
Mkt cap ! $1.744B | |||
| Open | High | Low | Value | Volume |
| $13.70 | $13.76 | $13.56 | $3.689M | 270.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 37 | $13.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.66 | 1132 | 2 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |